Tirofiban as Thrombolysis Adjunct for Patients with Acute Ischemic Stroke

Patients might have benefited from tirofiban, although these findings require confirmation before clinicians change their practice.

Intravenous (IV) thrombolysis with alteplase or tenecteplase is an established treatment for patients with acute ischemic stroke who can be treated within 4.5 hours. To learn whether an IV antiplatelet agent would have additional benefit after thrombolysis, researchers in China conducted a placebo-controlled study of patients with noncardioembolic stroke who met criteria for IV thrombolysis but did not qualify for thrombectomy.

Patients with atrial fibrillation were excluded. Tirofiban and placebo infusions lasted 24 hours. The 832 patients (mean age, 69 years; 36% women) had a median National Institutes of Health Stroke Scale score of 6. Stroke etiology was adjudicated to be large-vessel atherosclerotic in 58% and small-vessel occlusive in …

Reviewing Author

Seemant Chaturvedi, MD

Disclosures

Consultant/Advisory BoardBayer Pharmaceuticals; Novartis

Grant/Research SupportNational Institute of Neurological Disorders and Stroke

Editorial BoardsNeurology; Stroke

Seemant Chaturvedi, MD

Disclosures

Consultant/Advisory BoardBayer Pharmaceuticals; Novartis

Grant/Research SupportNational Institute of Neurological Disorders and Stroke

Editorial BoardsNeurology; Stroke

Tirofiban as Thrombolysis Adjunct for Patients with Acute Ischemic Stroke

Topics

Reviewing Author